Umang Shah, MD
Clinical Neurophysiology · Milwaukee, WINPI 1629212782
Payments from drug & device makers
Across 22 payments — averaging $206.20 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Grifols USA, LLC$2K
- Medtronic$1K
- Livanova USA, Inc.$760
- SK Life Science, Inc.$134
- Zogenix Inc.$49
- Biohaven Pharmaceutical Holding Company Ltd.$37
- plus $23 from 1 others
What the payments were for
- Travel & lodging$2,78361%
- Food & beverage$1,75339%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Grifols USA, LLC | 6 | $2,192 |
| Medtronic | 7 | $1,341 |
| Livanova USA, Inc. | 3 | $760 |
| SK Life Science, Inc. | 3 | $134 |
| Zogenix Inc. | 1 | $49 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $37 |
| Sunovion Pharmaceuticals Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Gamunex-C$2,166
- ACTIVA$1,088
- VNS - Sentiva$475
- VNS Therapy$285
How this compares
Too few clinical neurophysiology providers in Wisconsinto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BriviactBrivaracetam | 54 | $72,882 |
| Emgality PenGalcanezumab-Gnlm | 87 | $68,124 |
| Nurtec OdtRimegepant Sulfate | 44 | $59,955 |
| Aimovig AutoinjectorErenumab-Aooe | 40 | $38,056 |
| LamictalLamotrigine | 25 | $23,899 |
| Lacosamide | 161 | $16,458 |
| Levetiracetam | 345 | $9,156 |
| Lamotrigine | 125 | $4,111 |
| Carbamazepine | 44 | $4,047 |
| Clobazam | 61 | $3,903 |
| Oxcarbazepine | 36 | $3,739 |
| Gabapentin | 186 | $3,368 |
| Carbamazepine ErCarbamazepine | 16 | $3,096 |
| Zonisamide | 26 | $1,979 |
| Divalproex Sodium | 44 | $1,785 |
Paid to pharmacies, not to this prescriber.
Other clinical neurophysiology in Milwaukee
- Ikram KhanMilwaukee$35
- Janki LavingiaMilwaukee$16
- John BroderickMequon$671
- Brandon NideaMadison$432
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.